Aerie Pharmaceuticals Appoints Richard J. Rubino as Chief Financial Officer

Mr. Rubino brings over 30 years of experience, most recently as CFO of Medco Health Solutions

Aerie Pharmaceuticals Appoints Richard J. Rubino as Chief Financial Officer

Aerie PharmaceuticalsThomas van Haarlem, 908-470-4320President and Chief Executive OfficerorBurns McClellan, Inc.Justin JacksonorMichelle Szwarcberg212-213-0006orKathy Galante, 212-213-0006

Aerie Pharmaceuticals, a biotechnology company focused on the discovery and development of novel treatments for glaucoma, today announced the appointment of Richard J. Rubino to the position of Chief Financial Officer. Mr. Rubino has over 30 years of financial, business and strategic planning experience, most recently with Medco Health Solutions, Inc.

Thomas van Haarlem, M.D., President and Chief Executive Officer of Aerie Pharmaceuticals, commented, “Mr. Rubino joins Aerie at a very exciting time for the Company as we advance through Phase 2 clinical studies for two of our first-in-class products. His extensive financial leadership and strategic planning experience in the healthcare industry brings an important skill set to the management team. Also, Mr. Rubino’s strong networks in the financial and payor communities will play an important role in the growth and development of Aerie. We are pleased to have someone of Rich’s caliber join our Executive Team.”

Mr. Rubino commented, “I am delighted to join the Aerie team and look forward to working with my new colleagues in driving value through the rapid advancement of Aerie’s promising glaucoma pipeline. I feel privileged to join Aerie as we prepare for important clinical data and am very excited about prospects for the future success of the Company.”

Prior to joining Aerie, Mr. Rubino spent nearly 20 years at Medco, holding positions of increasing responsibility, including Chief Financial Officer and Chief Accounting Officer. During his tenure at Medco, Mr. Rubino was responsible for all aspects of Finance, including strategic and financial planning, accounting, treasury, SEC reporting and investor relations. Earlier, Mr. Rubino served in various accounting and business alliance positions with International Business Machines (IBM) Corporation, and was a Senior Auditor at Price Waterhouse & Co. Mr. Rubino received his BS in Accounting from Manhattan College. He is a Certified Public Accountant and a Member of the American Institute of Certified Public Accountants. Mr. Rubino is a board member and Treasurer of Northside Center for Child Development, a not-for-profit organization based in Harlem, New York.

Aerie Pharmaceuticals is a privately held, clinical-stage biotechnology company dedicated to the discovery and development of novel treatments for glaucoma. Aerie’s internal research and development engine has generated an innovative glaucoma pipeline. The Company’s lead product candidate, AR-12286, is a highly selective Rho-kinase (ROCK) inhibitor designed to lower intraocular pressure by improving outflow of fluid via the trabecular pathway with the potential of restoring normal function. Aerie currently is evaluating AR-12286 in multiple Phase 2 clinical studies as a standalone therapy and in combination with a commercially available prostaglandin. In addition, the Company is in Phase 2 clinical development for AR-13324, a novel product candidate with a dual mechanism of action that represents the first of a new proprietary class of glaucoma drugs. The Company is located in Bedminster, New Jersey and Research Triangle Park, North Carolina.

For more information on Aerie, please visit the Company’s website at .

Suggested Articles

Myovant’s uterine fibroid drug reduced blood loss in nearly three-quarters of patients, trouncing placebo in the second of two phase 3 studies.

The cystic fibrosis biotech unveiled Belous’ appointment alongside news of the promotion of Geoff Gilmartin to the CMO position.

The series C round is the latest in a series of boosts for Frequency’s attempts to tackle hearing loss through the activation of progenitor cells.